Effect of temozolomide in patients with metastatic bronchial carcinoids

Neuroendocrinology

Volumn 98, Issue 2, 2013, Pages 151-155

  Crona, Joakim ^b   Fanola, Irina ^a   Lindholm, Daniel P ^a   Antonodimitrakis, Pantelis ^a   Öberg, Kjell ^a   Eriksson, Barbro ^a   Granberg, Dan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Atypical carcinoid; Bronchial carcinoid; Chemotherapy; Metastatic disease; Typical carcinoid

Indexed keywords

TEMOZOLOMIDE; TROPISETRON;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BRONCHUS CARCINOID; BRONCHUS TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG EFFECT; OVERALL SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; COHORT STUDIES; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84886389266     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000354760     Document Type: Article

References (20)

1. Travis WD, Muller-Hermelink HK, Harris CC, Brambilla E: Tumours of the Lung, Pleura, Thymus and Heart. Pathology and Genetics. WHO Classification of Tumours. Lyon, IARC Press, 2004.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26:3063-3072.
3. Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, Muguruza I: Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-Centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007; 31:192-197.
4. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-944.
5. Granberg D, Eriksson B, Wilander E, Grim-fjärrd P, Fjällskog ML, Öberg K, Skogseid B: Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12: 1383-1391.
6. Wirth LJ, Carter MR, Jänne PA, Johnson BE: Outcome of patients with pulmonary carci-noid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44: 213-220.
7. Öberg K, Hellman P, Ferolla P, Papotti M: Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7):vii120-vii123.
8. Newlands ES, Blackledge GR, Slack JA, Ruslin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH: Phase I trial of temozolomide (CCRG 81045:M&B 39831:NSC 362856). Br J Cancer 1992; 65:287-291.
9. Middleton MR, Grob JJ, Aaronson N, Fierl-beck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher Nl: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
10. Stupp R, Mason WP, van den Bent JM, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Cur-schmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisen-hauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
11. Ekeblad S, Sundin A, Tiensuu Janson E, We-lin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Örlefors H, Sigurd M, Öberg K, Eriksson B, Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13:2986-2991.
12. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D; Barcelona Consensus Conference Participants: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95:120-134.
13. Crona J, Björklund P, Welin S, Kozlovacki G, Oberg K, Granberg D: Treatment, prognostic markers and survival in thymic neuroendo-crine tumours. A study from a single tertiary referral centre. Lung Cancer 2013; 79:289-293.
14. Lindholm DP, Eriksson B, Granberg D: Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroen-docrine carcinoma. Med Oncol 2012; 29:301-303.
15. Granberg D, Öberg K: Lung and thymic neu-roendocrine tumors; in Hay ID, Wass JA (eds): Clinical Endocrine Oncology. Oxford, Blackwell, 2008, pp 452-487.
16. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
17. Kulke M, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, At-tawia M, Lawrence C, Fuchs CS: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24:4044.
18. Fazio N, Granberg D, Grossman A, Saletan S, Klimowsky J, Panneerselvam A, Wolin EM: Everolimus plus octreotide LAR in patients with advanced lung neuroendocrine tumors: analysis of the phase III, randomized, placebo-controlled RADIANT-2 study. Chest 2013; 14:955-962.
19. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temo-zolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
20. 177Lu-octreotate in combination with capecitabine and temo-zolomide in advanced low-grade neuroendo-crine tumors. Cancer Biother Radiopharm 2012; 27:561-569.